LTZ Therapeutics
LTZ Therapeutics develops cancer immunotherapies that target myeloid biology.
$38MUndisclosed
Role not disclosedGV
GL Ventures
Activity from announced rounds
Activity in this selectionMay 31, 2026 · AI · May 1, 2026
GL Ventures is the Hillhouse-origin early-stage venture firm identified in LTZ and Clipto issuer announcements.
Recorded funding activity
LTZ develops cancer immunotherapies targeting myeloid biology. Clipto supplies tools for searching video and audio libraries, while Anew combines AI models and experiments for drug discovery. These histories remain distinct from the Hillhouse parent and named funds.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $38M 1 disclosed · full round size, not this investor’s share